I don't know why Allergan is buying this struggling penny stock company. I don't think Allergan can do what Repros couldn’t and deliver the safety data that the FDA is looking for.
I don't think Allergan cares. The company was dirt cheap at $0.67/share so pick it up on the off chance it gets approved. Two birds killed - potential competition and potential add to the portfolio. It was a spit in the bucket financially.
The truth is there are providers already using testosterone to treat uterine fybroids. Now, the question is how will Allergan get the study completed and convince the FDA?
This is a great deal, BS will throw the vast array Allergan R&D talent at this and we will add another fine product to the portfolio.......oh no wait.....doh!
They paid $26M for a chance...to put it in perspective, BS makes about $35M/year...so this wasn't even a blip on the radar.
This deal is like all the other M&A deals that Saunders has spent money on. It's a roll of the dice. Potentially a smart move since Esmya could have liver issues and if they are able to develop Repros' drug then they might have made a wise purchase. Payback could be huge!
Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism. Any waste of $26Million by Saunders. Is the board paying attention to this guys stupidiity??????
Hey dumbass- We bought them because we want to develop their Uterine Fibroid drug which they cant cause they dont have the capabilities since our drug seems to have serious issues. F'ing stupid MF'er sales monkey!
